(S)-N-BOC-2-(5-溴噻吩)苯胺 | 190319-95-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - BOC-氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-N-BOC-2-(5-溴噻吩)苯胺
• 中文别名: BOC-L-2-(5-溴噻吩基)丙氨酸
• 英文名称: (S)-3-(5-Bromothiophen-2-yl)-2-((tert-butoxycarbonyl)amino)propanoic acid
• 英文别名: (2S)-3-(5-bromothiophen-2-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 190319-95-0
• 化学式: C₁₂H₁₆BrNO₄S
• 分子量: 350.23
• InChiKey: HHNNFRCLMQFXBA-QMMMGPOBSA-N

物化性质

• 熔点：
  70.3 °C
• 沸点：
  473.8±45.0 °C(Predicted)
• 密度：
  1.4628 (estimate)
• 稳定性/保质期：
  <p>遵循规定使用和储存，则不会分解。</p>

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 安全说明：
  S24/25
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  (S)-N-BOC-2-(5-溴噻吩)苯胺 、 N,N-二异丙基乙胺 、 碘甲烷 、 水 在 乙酸乙酯 、 盐酸 、 disodium;carbonate 、 Sodium sulfate-III 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 以to furnish (S)-3-(5-bromo-thiophen-2-yl)-2-tert-butoxycarbonylamino-propionic acid methyl ester的产率得到methyl 3-(5-bromo-2-thienyl)-N-(tert-butoxycarbonyl)-L-alaninate
  参考文献：
  名称：

  Substituted azoanthracene derivatives and intermediates for preparation thereof

  摘要：

  本发明涉及取代的偶氮蒽衍生物及其制备中间体。这些取代的偶氮蒽衍生物和相关的中间体可用于制备药物组合物，用于治疗或预防调节人类GLP-1受体有益的疾病、疾病和状况。

  公开号：

  US09175003B2

文献信息

• Substituted hydantoins
  申请人：Chen Shaoqing

  公开号：US20070197617A1

  公开（公告）日：2007-08-23

  The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.

  本发明涉及公式化合物的方法，其制备方法以及它们的使用方法。这些化合物在治疗由MEK高活性特征的疾病中很有用。因此，这些化合物在治疗癌症、认知和中枢神经系统疾病以及炎症/自身免疫疾病等疾病中很有用。
• METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS
  申请人：Niu Huifeng

  公开号：US20080207563A1

  公开（公告）日：2008-08-28

  Disclosed are methods for synergistically inhibiting the proliferation of tumor cells by contacting the tumor cells with a MEK inhibitor compound and erlotinib, either sequentially or simultaneously. Also disclosed are methods for inhibiting the proliferation of tumor cells in a human, by administering to the human, sequentially or simultaneously, an amount of erlotinib and a MEK inhibitor compound, wherein the amounts are effective, in combination, to synergistically inhibit the proliferation of the tumor cells in the human.

  本文揭示了通过将肿瘤细胞与MEK抑制剂化合物和厄洛替尼接触，无论是顺序地还是同时地，协同抑制肿瘤细胞增殖的方法。还揭示了通过向人体逐步或同时施用厄洛替尼和MEK抑制剂化合物的方法，其中这些量在组合时对于协同抑制人体内肿瘤细胞增殖是有效的。
• [EN] SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C<br/>[FR] INHIBITEURS DE CATHEPSINE C DE TYPE (CYANO-MÉTHYL)-AMIDES D'ACIDE 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIQUE SUBSTITUÉ
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014140078A1

  公开（公告）日：2014-09-18

  This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides of formula (1) and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

  这项发明涉及式（1）的2-Aza-bicyclo[2.2.1]庚烷-3-羧酸（氰基甲基）酰胺及其作为Cathepsin C抑制剂的用途，含有该化合物的药物组合物，以及将其用作治疗和/或预防与二肽基肽酶I活性相关的疾病，例如呼吸道疾病的药物的方法。
• SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Mjalli Adnan M.M.

  公开号：US20110160198A1

  公开（公告）日：2011-06-30

  The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.

  本发明涉及替代的偶氮蒽衍生物或其药学上可接受的盐，其调节人类GLP-1受体，并可用于治疗调节人类GLP-1受体有益的疾病、紊乱或病症，如2型糖尿病。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在治疗调节人类GLP-1受体有益的这些疾病、紊乱或病症中的使用。
• Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
  申请人：Mjalli Adnan M. M.

  公开号：US08383644B2

  公开（公告）日：2013-02-26

  The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.

  本发明涉及取代的偶氮蒽衍生物或其药学上可接受的盐，其调节人类GLP-1受体，并可在治疗调节人类GLP-1受体有益的疾病、疾病、或病情，如2型糖尿病。本发明还涉及包含这些化合物的制药组合物，以及在治疗这些有益的疾病、疾病或病情中使用这些化合物和组合物。